Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice (2017)

  • Authors:
  • USP affiliated authors: CALDINI, ELIA TAMASO ESPIN GARCIA - FM ; CONDINO NETO, ANTONIO - ICB ; ZATZ, MAYANA - IB ; NUNES, BRUNO GHIROTTO - IB
  • USP Schools: FM; ICB; IB; IB
  • DOI: 10.1038/s41431-017-0017-y
  • Subjects: SISTEMA IMUNE; IMUNOGLOBULINAS; DOENÇAS AUTOIMUNES
  • Agências de fomento:
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1038/s41431-017-0017-y (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: bronze

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      NUNES, Bruno Ghirotto; LOURES, Flavio Vieira; BUENO, Heloisa Maria Siqueira; et al. Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice. European journal of human genetics, London, Nature Publishing Group, v. 25, n. 12, p. 1388-1396, 2017. Disponível em: < http://dx.doi.org/10.1038/s41431-017-0017-y > DOI: 10.1038/s41431-017-0017-y.
    • APA

      Nunes, B. G., Loures, F. V., Bueno, H. M. S., Cangussu, E. B., Guimarães, E. da S. G., Coatti, G. C., et al. (2017). Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice. European journal of human genetics, 25( 12), 1388-1396. doi:10.1038/s41431-017-0017-y
    • NLM

      Nunes BG, Loures FV, Bueno HMS, Cangussu EB, Guimarães E da SG, Coatti GC, Caldini ETEG, Condino Neto A, Zatz M. Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice [Internet]. European journal of human genetics. 2017 ; 25( 12): 1388-1396.Available from: http://dx.doi.org/10.1038/s41431-017-0017-y
    • Vancouver

      Nunes BG, Loures FV, Bueno HMS, Cangussu EB, Guimarães E da SG, Coatti GC, Caldini ETEG, Condino Neto A, Zatz M. Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice [Internet]. European journal of human genetics. 2017 ; 25( 12): 1388-1396.Available from: http://dx.doi.org/10.1038/s41431-017-0017-y

    Referências citadas na obra
    Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJ, Kunkel LM. The pathogenesis and therapy of muscular dystrophies. Annu Rev Genom Hum Genet. 2015;16:281–308.
    Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5:872–76.
    Bengtsson NE, Hall JK, Odom GL, et al. Muscle specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun. 2017;8. https://doi.org/10.1038/ncomms14454 .
    Van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001;10:1547–54.
    Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005;84:843–50.
    Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield LM, Woodcock J. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015;7:299.
    Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. Helper (CD4+) and Cytotoxic (CD8+) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol. 2001;98:235–43.
    Jolles S, Jordan SC, Orange JS, van Schaik IN. Immunoglobulins: current understanding and future directions. Clin Exp Immunol. 2014;178:163–8.
    Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13:176–89.
    Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med. 2007;204:11–5.
    Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367–75.
    Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allerg Clin Immunol. 2011;127:315–23.
    Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy. Nat Rev Neurol. 2015;11:80–9.
    Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7:349–59.
    Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693–702.
    Zschüntzsch J, Zhang Y, Klinker F, et al. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy. J Neurochem. 2016;136:351–62.
    McGreevy JW, Hakim CH, McIntosh MA, Duan D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech. 2015;8:195–213.
    Deconinck AE, Rafael JA, Skinner JA, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 1997;90:717–27.
    Farini A, Sitzia C, Cassani B, et al. Therapeutic potential of immunoproteasome inhibition in Duchenne muscular dystrophy. Mol Ther. 2016;24:1898–1912.
    Zatz M, Vieira NM, Zucconi E, et al. A normal life without muscle dystrophin. Neuromuscul Disord. 2015;25:371–4.
    Vieira NM, Guo LT, Estrela E, Kunkel LM, Zatz M, Shelton GD. Muscular dystrophy in a family of labrador retrievers with no muscle dystrophin and a mild phenotype. Neuromuscul Disord. 2015;25:363–70.
    Vieira NM, Elvers I, Alexander MS, et al. Jagged 1 rescues the duchenne muscular dystrophy phenotype. Cell. 2015;163:1204–13.
    Villalta SA, Rosenberg AS, Bluestone JA. The immune system in Duchenne muscular dystrophy: friend or foe. Rare Dis. 2015;3. https://doi.org/10.1080/21675511.2015.1010966 .
    Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758–65.
    Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med. 2010;362:1429–37.
    Sitzia C, Farini A, Jardim L, et al. Adaptive immune response impairs the efficacy of autologous transplantation of engineered stem cells in dystrophic dogs. Mol Ther. 2016;24:1949–64.
    Ferrer A, Wells KE, Wells DJ. Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Gene Ther. 2000;7:1439–46.
    Tidball JG. Regulation of muscle growth and regeneration by the immune system. Nat Rev Immunol. 2017;17:165–78.
    Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol. 2010;298:1173–87.
    Londhe P, Davie JK. γ-Interferon modulates myogenesis through the major histocompatibility complex class II transactivator, CIITA. Mol Cell Biol. 2011;31:2854–66.
    Londhe P, Davie JK. Interferon-γ resets muscle cell fate by stimulating the sequential recruitment of JARID2 and PRC2 to promoters to repress myogenesis. Sci Signal. 2013;6:ra107.
    Acharyya S, Sharma SM, Cheng AS, et al. TNF inhibits NOTCH1 in skeletal muscle cells by EZH2 and DNA methylation mediated repression: implications in Duchenne muscular dystrophy. PLoS One. 2010;5:e12479. https://doi.org/10.1371/journal.pone.0012479
    Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994;97:79–83.
    Godeuau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359:23–9.